Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 19Recruiting 5Terminated 4Unknown 3Withdrawn 2No longer available 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Thoracic 1

Conditions

Sarcoma 2Lung Neoplasms 1Liposarcoma, Myxoid 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leiomyosarcoma 1

Interventions

Radiotherapy 5Gemcitabine 4Cyclophosphamide 4pazopanib 3Docetaxel 3Biopsy 3pembrolizumab 2olaparib 2liposomal doxorubicin 2Vincristine 2Trastuzumab 2Trabectedin 2Temozolomide 2Taxes 2Surgical Procedures, Operative 2Specimen Handling 2Proton Therapy 2Nivolumab 2Magnetic Resonance Spectroscopy 2Ifosfamide 2Filgrastim 2Etoposide 2Drug Therapy 2Doxorubicin 2Celecoxib 2Carboplatin 2Ascorbic Acid 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2trastuzumab biosimilar HLX02 1tozuleristide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Sarcoma × Trabectedin × Clear all
NCT03397186 2019-09-10

Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma

Fred Hutchinson Cancer Center

Phase 2 Withdrawn
Sarcoma

Sarcoma, Liposarcoma, Myxoid

NCT03496519 2018-10-09

Assessing the Combination of Durvalumab (MEDI4736) and Trabectedin in Solid Tumors

University of Colorado, Denver

Phase 1 Withdrawn
SarcomaThoracic

Lung Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡